MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Progressive supranuclear palsy(PSP)"

  • 2018 International Congress

    Prevalence and characteristics of patients with progressive supranuclear palsy (PSP) in US health insurance claims data

    E. Viscidi, T. Dam, M. Juneja, L. Li, H. Krzywy, S. Eaton, S. Chen, S. Hall, A. Dilley (Cambridge, MA, USA)

    Objective: To estimate the prevalence of PSP in the United States (US) and present a profile of PSP patients. Background: Progressive supranuclear palsy (PSP) is…
  • 2018 International Congress

    Burden among Patients with Progressive Supranuclear Palsy

    T. Xie, X. Ye, L. Kandukuri, Y. Bao (Chicago, IL, USA)

    Objective: To quantify the economic costs and examine the most common co-morbidities of patients with progressive supranuclear palsy (PSP) in the United States. Background: PSP…
  • 2018 International Congress

    Midbrain Diameter Measurements on High-Resolution Computer Tomography Scans to aid diagnosis of Progressive Supranuclear Palsy

    S. Potluri, C. Gan, C. Thomas, B. Mohamed, S. Schwarz (Cardiff, United Kingdom)

    Objective: To establish whether high-resolution computer tomography (CT) scans can aid the diagnosis of progressive supranuclear palsy (PSP), and multiple system atrophy (MSA). Background: The…
  • 2018 International Congress

    Burden of progressive supranuclear palsy: A systematic literature review

    S. Chen, I. Jakab, T. Zelei, L. Szilberhorn, R. Bendes, B. Elezbawy, Z. Kaló, M. Mann, M. Potashman, J. Pitter (Cambridge, MA, USA)

    Objective: The objective of this research was to identify available data on burden of progressive supranuclear palsy (PSP), a 4-repeat tauopathy. Research questions focused on…
  • 2018 International Congress

    Accuracy of the International Parkinson Disease and Movement Disorder Society Progressive Supranuclear Palsy Diagnostic Criteria (IPD-MDS-PSP)

    A. Shoeibi, I. Litvan, J. Juncos, Y. Bordelon, D. Riley, S. Reich, D. Shprecher, D. Hall, C. Marras, B. Kluger, N. Olfati, J. Jankovic (Mashhad, Islamic Republic of Iran)

    Objective: To evaluate the accuracy of the IPD-MDS-PSP criteria to differentiate PSP-Richardson (PSP-R) from PSP-parkinsonism (PSP-P), the most common PSP phenotypes. Background: The new International…
  • 2018 International Congress

    The clinical spectrum of motor stereotypies in progressive supranuclear palsy: An early, frequent and underestimated symptom

    J. Pagonabarraga, A. Horta-Barba, I. Illan, I. Aracil, H. Bejr-Kasem, J. Pérez-Pérez, J. Marín-Lahoz, B. Pascual-Sedano, S. Martinez-Horta, J. Kulisevsky (Barcelona, Spain)

    Objective: To describe the frequency, phenomenology, and clinical and neuropsychological correlates of stereotypies in PSP. Background: Stereotypies are repetitive, patterned and predictable purposeless movements. Unlike…
  • 2018 International Congress

    Comparative study of non-motor symptoms in patients with progressive supranuclear palsy and age, gender, duration of illness matched patients with Parkinson’s disease

    V. Holla, C. SP, A. Lenka, A. Stezin, S. Prasad, N. Kamble, R. Yadav, P. Pal (Bengaluru, India)

    Objective: To assess the frequency of NMS in PSP and compare them to age, gender and duration of illness matched PD patients. Background: Non-motor symptoms…
  • 2018 International Congress

    Methylphenidate in Progressive Supranuclear Palsy [PSP] – Old drug, New Indications?

    N. Sawal, P. Bansal, R. Gupta (Chandigarh, India)

    Objective: To evaluate whether Methylphenidate can improve some symptoms of PSP. Background: PSP is a neurodegenerative disorder with limited therapeutic options. Methylphenidate[MPH] , a drug…
  • 2018 International Congress

    Role of uric acid as a prognostic biomarker in Idiopathic Parkinson’s disease and Parkinson Plus Syndrome

    T. Modi, M. Goyal, J. Kaur, B. Medhi (Chandigarh, India)

    Objective: To estimate the levels of serum uric acid in Idiopathic Parkinson’s disease (IPD) and various Parkinson plus syndromes (PPS). To correlate the uric acid…
  • 2017 International Congress

    Which clinical features predict progressive supranuclear palsy pathology? A clinicopathological study on 437 autopsy cases and a literature review

    G. Respondek, C. Kurz, T. Arzberger, E. Gelpi, D. Irwin, W. Meissner, A. Pantelyat, A. Rajput, J. Van Swieten, C. Troakes, K. Josephs, A. Lang, U. Mueller, C. Nilsson, Y. Bordelon, J.-C. Corvol, A. Boxer, L. Golbe, I. Litvan, M. Stamelou, G. Hoeglinger (Munich, Germany, Germany)

    Objective: To identify clinical features and investigations which predict PSP pathology during lifetime in the largest pathology PSP cohort reported to date compared to autopsy…
  • « Previous Page
  • 1
  • …
  • 37
  • 38
  • 39
  • 40
  • 41
  • …
  • 49
  • Next Page »

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley